New drug may become the new standard of care for patients with small cell lung cancer, SCLC
Don't miss opportunities to get drugs like this in a clinical trial setting! Why? Lurbinectedin monotherapy as a second-line therapy in patients with small cell lung cancer, SCLC, elicited a…